Neurofibromatosis Type 1 : A General Review

Area of Science:

• Genetics and Molecular Biology
• Clinical Medicine
• Pediatrics

Background:

• Neurofibromatosis type 1 (NF1) is an autosomal-dominant genetic disorder caused by pathogenic variants in the NF1 gene.
• Affecting approximately 1 in 3,000 individuals worldwide, NF1 presents with a heterogeneous clinical phenotype that evolves throughout life.
• Key features include café-au-lait macules, freckling, neurofibromas (cutaneous and plexiform), and optic-pathway gliomas.

Purpose of the Study:

• To review the current understanding of Neurofibromatosis type 1 (NF1), focusing on diagnostic advancements and therapeutic progress.
• To emphasize the importance of multidisciplinary care, early diagnosis, and tailored health surveillance for individuals with NF1.
• To highlight strategies for mitigating NF1 complications and enhancing patient quality of life.

Main Methods:

• Review of advanced molecular diagnostic techniques, including next-generation sequencing (NGS) and RNA sequencing, for improved mutation detection.
• Analysis of recent therapeutic advancements, specifically the FDA approval of MEK inhibitors (selumetinib, mirdametinib) for plexiform neurofibromas.
• Synthesis of recommendations for age-stratified health surveillance, cancer prevention, and genetic counseling in NF1 management.

Main Results:

• Advanced molecular diagnostics have significantly improved mutation detection rates and facilitated definitive NF1 diagnosis.
• MEK inhibitors have shown efficacy in treating plexiform neurofibromas and may benefit other NF1 manifestations.
• NF1 impacts skeletal integrity, neurocognitive function, and increases malignancy risk, necessitating comprehensive management.

Conclusions:

• Multidisciplinary care is essential for individuals with NF1, integrating early diagnosis, continuous health surveillance, and genetic counseling.
• Targeted therapies, such as MEK inhibitors, represent significant progress in managing NF1-related plexiform neurofibromas.
• A proactive and comprehensive approach to NF1 care is crucial for mitigating disease complications and improving long-term quality of life.